HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bekhit, M. T Articles by Greenwood, P. A Search for Related Content PubMed Articles by Bekhit, M. T Articles by Greenwood, P. A

Reappraisal of the use of clomifene for ovulation induction

Staff Doctor in Obstetrics and Gynaecology, James Paget Heathcare NHS Trust, Lowestoft Road, Gorleston, Great Yarmouth, Norfolk, NR31 6LA, UK. email: mtbekhit{at}yahoo.co.uk (corresponding author)

Peter A Greenwood, FRCOG FRCS Ed, Consultant

James Paget Heathcare NHS Trust, Norfolk, UK.

Ovulatory disorders represent at least 20% of causes of infertility. Women suffering from polycystic ovary syndrome are considered a subgroup of the World Heath Organization Group II ovulatory disorders, accounting for 80% of all cases of anovulation. Clomifene has traditionally been the first line of treatment, followed by gonadotrophins as a second line. However, changing concepts and better understanding of the pathophysiology of ovulatory disorders, particularly polycystic ovary syndrome, have allowed modification of the traditional approach. We describe a more individually tailored approach for ovulation induction based on the characteristics of each woman's initial screening. This is more likely to result in a further improvement of the balance between the chances of success versus complications, while keeping down the cost of treatment.

Keywords Keywords / alternative strategies / clomifene / individually tailored approach / ovulation induction